Agile Therapeutics, Inc. (AGRX)
- Previous Close
0.3800 - Open
0.3945 - Bid 0.5833 x 200
- Ask 0.5669 x 100
- Day's Range
0.3690 - 0.3950 - 52 Week Range
0.2000 - 7.0000 - Volume
15,897 - Avg. Volume
729,745 - Market Cap (intraday)
2.701M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-6.7100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
www.agiletherapeutics.com19
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AGRX
Performance Overview: AGRX
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGRX
Valuation Measures
Market Cap
2.70M
Enterprise Value
2.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.04
Price/Book (mrq)
--
Enterprise Value/Revenue
0.12
Enterprise Value/EBITDA
-0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
-73.83%
Return on Assets (ttm)
-101.46%
Return on Equity (ttm)
--
Revenue (ttm)
19.59M
Net Income Avi to Common (ttm)
-14.46M
Diluted EPS (ttm)
-6.7100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.56M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.68M